2 Novel Treatments For Retinitis Pigmentosa Move Closer To Clinical Trials
"While these therapies still need to be refined, the results are highly encouraging," said Stephen H. Tsang, MD, PhD, associate professor of pathology & cell biology and of ophthalmology at Columbia University Medical Center and an ophthalmologist at NewYork-Presbyterian Hospital/CUMC, the leader of both studies. "We've never seen this type of improvement in retinal function in mouse models of RP. We hope we may finally have something to offer patients with this form of vision loss."
The stem cell study was published in the journal Molecular Medicine. The gene therapy study was published in Human Molecular Genetics.
RP encompasses a group of inherited eye diseases that cause progressive loss of photoreceptor cells, specialized neurons found in the retina. While RP can appear during infancy, the first symptoms typically appear in early adulthood, beginning with night blindness. As the disease progresses, affected individuals lose peripheral vision. In later stages, RP destroys photoreceptors in the macula, which is responsible for fine central vision. Mutations in at least 50 genes have been found to cause the disease, which affects about 1.5 million people worldwide.
In the Molecular Medicine study, the CUMC researchers tested the long-term safety and efficacy of using iPS cell grafts to restore visual function in a mouse model of RP. Like embryonic stem cells, iPS cells are "pluripotent" - that is, they are capable of developing into any cell type. However, iPS cells are not derived from embryos but from adult cells, in this case from human skin cells. The cells were administered, via injection directly underneath the retina, when the mice were five days old.
The iPS cells assimilated into the host retina without disruption, and none of the mice receiving transplants developed tumors over their lifetimes, the researchers reported. The iPS cells were found to express markers specific to retinal pigmented epithelium (the cell layer adjacent to the photoreceptor layer), showing that they had the potential to develop into functional retinal cells. Using electroretinography, a standard method for measuring retinal function, the researchers found that the visual function of the mice improved after treatment and the effect was long lasting. "This is the first evidence of lifelong neuronal recovery in an animal model using stem cell transplants, with vision improvement persisting throughout the lifespan," said Dr. Tsang.
In 2011, the FDA approved clinical trials of embryonic stem cell transplants for the treatment of macular degenerations, but such therapy requires immunosuppression. "Our study focused on patient-specific iPS cells, which offer a compelling alternative," said Dr. Tsang. "The iPS cells can provide a potentially unlimited supply of cells for functional rescue and optimization. Also, since they would come from the patient's own body, immunosuppression would not be necessary to prevent rejection after transplantation."
In theory, iPS cell transplants could also be used to treat age-related macular degeneration, the leading cause of vision loss among older adults, said Dr. Tsang.
In the Human Molecular Genetics study, the CUMC researchers tested whether gene therapy could be used to improve photoreceptor survival and neuronal function in mice with RP caused by a mutation to a gene called phosphodiesterase-alpha (Pde6α) - a common form of the disease in humans. To treat the mice, the researchers used adeno-associated viruses (AAV) to ferry correct copies of the gene into the retina. The AAV were administered by a single injection in one eye, with the other eye serving as a control.
When the mice were examined at six months of age (over one-third of the mouse lifespan), photoreceptor cells were found in the treated eyes but not in the untreated eyes, the researchers reported. More important, the treated eyes showed functional visual responses, while the untreated eyes had lost all vision.
"These results provide support that RP due to PDE6α deficiency in humans is also likely to be treatable by gene therapy," said Dr. Tsang.
CUMC and its teaching-hospital affiliate, NewYork-Presbyterian Hospital, are part of an international consortium that was recently formed to bring this PDE6A gene therapy to patients. Pending FDA approval, Phase I/II clinical trials could begin within a year.
The Molecular Medicine paper is titled, "Stem Cell (iPS) Grafts in a Preclinical Model of Retinitis Pigmentosa." The other contributors are Yao Li (CUMC), Yi-Ting Tsai (CUMC), Chun-Wei Hsu (CUMC), Deniz Erol (CUMC), Jin Yang (CUMC), Wen-Hsuan Wu (CUMC), Richard J Davis (CUMC), and Dieter Egli (New York Stem Cell Foundation Laboratory). This study was supported by the NYSTEM co26448, National Institutes of Health (grants 5P30CA013696 and P30EY019007), Research to Prevent Blindness, the Joan and Michael Schneeweiss Stem Cell Fund, and the Foundation Fighting Blindness.
The Human Molecular Genetics paper is titled, "Gene therapy provides long-term visual function in a pre-clinical model of retinitis pigmentosa." The other contributors are Katherine J. Wert (CUMC), Richard J. Davis (CUMC), Javier Sancho-Pelluz (CUMC), and Patsy M. Nishina (Jackson Laboratory, Bar Harbor, Maine). The research was supported by the National Institute of Health (grants 5P30EY019007 and R01EY018213), the National Cancer Institute (grant 5P30CA013696), Research to Prevent Blindness, the Department of Defense (grant TS080017-W81XWH-09-1-0575), the Foundation Fighting Blindness, the Joan and Michael Schneeweiss Stem Cell Fund, the Barbara and Donald Jonas Family Fund, and the Tistou and Charlotte Kerstan Foundation.
The authors of both studies declare no financial or other conflicts of interest.
Columbia University Medical Center
Source: EurekAlert!, the online, global news service operated by AAAS, the science society
Please use one of the following formats to cite this article in your essay, paper or report:
Columbia University Medical Center. "2 Novel Treatments For Retinitis Pigmentosa Move Closer To Clinical Trials." Medical News Today. MediLexicon, Intl., 2 Jan. 2013. Web.
1 Oct. 2016. <http://www.medicalnewstoday.com/releases/254385.php>
Columbia University Medical Center. (2013, January 2). "2 Novel Treatments For Retinitis Pigmentosa Move Closer To Clinical Trials." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.